Self-Assembling Nanoparticles Orchestrate Cuproptosis-Immunotherapy Synergy to Suppress Postoperative Glioma Recurrence
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.5c19127 ↗At a glance
Journal article in ACS Applied Materials & Interfaces, 2025. Written by Chao Zhang and 13 co-authors. Institution: Department of Neurosurgery, The Affliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou 239000, China. Major MEDLINE topics: Nanoparticles, Copper, Temozolomide, Immunotherapy. Cited 11 times so far (Crossref); 44 references. Funded by: Scientific Research Foundation of Education Department of Anhui Province of China, Chuzhou Science and Technology Program, Health Research Program of Chuzhou.
Abstract (original language)
Glioblastoma (GBM), the most aggressive primary malignant tumor of the central nervous system, poses significant therapeutic challenges. Standard treatments, including maximal surgical resection combined with temozolomide (TMZ) chemotherapy and radiotherapy, provide only temporary relief from tumor progression and are inadequate in preventing recurrence. Recurrent GBM often displays a more aggressive phenotype, marked by heightened malignancy and tumor stem cell traits, further complicating clinical management. To overcome these limitations, we have devised an albumin-based nanodelivery system (BSA@CTW-NPs) for the synergistic delivery of two therapeutic agents: wogonoside, a potent antitumor compound derived from traditional Chinese medicine, and TMZ, the frontline chemotherapeutic drug for GBM. This system uniquely incorporates Cu2+ as a modulator of the tumor microenvironment (TME) to amplify oxidative stress through a Fenton-like reaction. Additionally, we have employed a postoperative in situ implantation strategy utilizing hemostatic sponges, harnessing the power of chemodynamic therapy (CDT) and cuproptosis to exert antitumor effects. This approach also triggers immunogenic cell death (ICD), thereby activating a potent antitumor immune response. Our combined strategy significantly enhances tumor cell eradication and suppresses postoperative recurrence, presenting a promising translational framework for improving clinical outcomes in GBM.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurosurgery, The Affliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou 239000, China.
- Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
- Department of Gastrointestinal Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361000, China.
- Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, China.
- School of Biomedical Engineering, Anhui Medical University, Hefei 230032, China.
- Affiliated Chuzhou Hospital of Anhui Medical University, Chuzhou 239000, China.
ORCID profiles: Chao Zhang, Shiqiang Hou
Funding
- Scientific Research Foundation of Education Department of Anhui Province of China
- Chuzhou Science and Technology Program
- Health Research Program of Chuzhou
Cite
APA
Zhang, C., Hou, S., Hu, B., Wu, Z., Li, X., Yu, D., Shi, X., Wang, S., Wang, Y., Sun, Z., Wang, C., Peng, Q., Liang, Z., & Lin, N. (2025). Self-Assembling Nanoparticles Orchestrate Cuproptosis-Immunotherapy Synergy to Suppress Postoperative Glioma Recurrence. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c19127
Vancouver
Zhang C, Hou S, Hu B, Wu Z, Li X, Yu D, et al. Self-Assembling Nanoparticles Orchestrate Cuproptosis-Immunotherapy Synergy to Suppress Postoperative Glioma Recurrence. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c19127
BibTeX
@article{Zhang2025,
author = {Zhang, Chao and Hou, Shiqiang and Hu, Ben and Wu, Ziying and Li, Xinwei and Yu, Dong and Shi, Xingjie and Wang, Shuai and Wang, Yu and Sun, Zhiming and Wang, Chao and Peng, Qian and Liang, Zhen and Lin, Ning},
title = {Self-Assembling Nanoparticles Orchestrate Cuproptosis-Immunotherapy Synergy to Suppress Postoperative Glioma Recurrence},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.5c19127}
}
EUVIMED